title: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.
abstract: OBJECTIVE
  To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma.
  
  
  METHODS
  Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy. Thirty patients without prior chemotherapy and 16 pretreated with cisplatin-based chemotherapy were assessable for toxicity and response. VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.
  
  
  RESULTS
  Six of 30 patients (20%) without prior chemotherapy achieved a partial response (PR) (95% confidence interval [CI], 8% to 39%). The median duration of response was 21 weeks (range, 17 to 28). One of 16 patients (6%) with prior chemotherapy had a complete response (CR) of 31 weeks' duration (95% CI, 0% to 30%). The overall response rate (World Health Organization [WHO] criteria) was 15% (CR, 2%; PR 13%; 95% CI, 6% to 29%). The median dose-intensity (DI) was 20 mg/m2/wk. VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred. At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients. A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred. Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).
  
  
  CONCLUSIONS
  These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma. Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.
authors.affiliation: Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, France.
authors.forename: T
authors.initials: T
authors.lastname: Conroy
authors.forename: P L
authors.initials: PL
authors.lastname: Etienne
authors.forename: A
authors.initials: A
authors.lastname: Adenis
authors.forename: D J
authors.initials: DJ
authors.lastname: Wagener
authors.forename: B
authors.initials: B
authors.lastname: Paillot
authors.forename: E
authors.initials: E
authors.lastname: François
authors.forename: L
authors.initials: L
authors.lastname: Bedenne
authors.forename: J H
authors.initials: JH
authors.lastname: Jacob
authors.forename: J F
authors.initials: JF
authors.lastname: Seitz
authors.forename: H
authors.initials: H
authors.lastname: Bleiberg
authors.forename: C
authors.initials: C
authors.lastname: Van Pottelsberghe
authors.forename: M
authors.initials: M
authors.lastname: Van Glabbeke
authors.forename: F M
authors.initials: FM
authors.lastname: Delgado
authors.forename: S
authors.initials: S
authors.lastname: Merle
authors.forename: J
authors.initials: J
authors.lastname: Wils
mesh_terms: D015746:Abdominal Pain / Q000139:chemically induced; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D012021:Reflex, Abnormal; D012026:Reflex, Stretch; D015996:Survival Rate; D016896:Treatment Outcome; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine